Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis

Lv, Qingyu; Gong, Liuyang; Zhang, T.; Ye, J.; Chai, Limin; Mao, Yuliang

doi:10.1007/s12094-015-1372-1

Cited by 62 publications

(33 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical endpoints were PFS and OS. PFS and OS were calculated from the time of the first draw for CTCs or ctDNA until the progression (assessed using RECIST criteria) or death, respectively (22,23,(28)(29)(30)(31).…”

Section: Discussionmentioning

confidence: 99%

Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

Rossi

Rademaker

et al. 2018

Clinical Cancer Research

120

View full text Add to dashboard Cite

Purpose: Liquid biopsy provides a real-time assessment of metastatic breast cancer (MBC). We evaluated the utility of combining circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) to predict prognosis in MBC.Experimental Design: We conducted a retrospective study of 91 patients with locally advanced breast cancer and MBC. CTCs were enumerated by CellSearch; the plasma-based assay was performed utilizing Guardant360 and the survival analysis using Kaplan-Meier curves.Results: Eighty-four patients had stage IV cancer, and 7 patients had no metastases. Eighty patients had CTC analysis: median number 2 (0-5,612). Blood samples [232 of 277 (84%)] had mutations. The average ctDNA fraction was 4.5% (0-88.2%) and number of alterations 3 (0-27); the most commonly mutated genes were TP53 (52%), PIK3CA (40%), and ERBB2 (20%). At the time of analysis, 36 patients (39.6%) were dead. The median follow-up for CTCs was 9 months; for ctDNA, it was 9.9 months. For CTCs and ctDNA, respectively, progression-free survival (PFS) was 4.2 and 5.2 months and overall survival (OS) was 18.7 and 21.5 months. There was a statistically significant difference in PFS and OS for baseline CTCs < 5 versus CTCs ! 5 (P ¼ 0.021 and P ¼ 0.0004, respectively); %ctDNA < 0.5 versus ! 0.5 (P ¼ 0.003 and P ¼ 0.012); number of alterations < 2 versus ! 2 (P ¼ 0.059 borderline and P ¼ 0.0015). A significant association by Fisher exact test was found between the number of alterations and the %ctDNA in the baseline sample (P < 0.0001).Conclusions: The study demonstrated that liquid biopsy is an effective prognostic tool. Clin Cancer Res; 24(3); 560-8. Ó2017 AACR.

show abstract

Section: Discussionmentioning

confidence: 99%

Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

Rossi

Rademaker

et al. 2018

Clinical Cancer Research

120

View full text Add to dashboard Cite

show abstract

“…The meta-regression analysis results showed that clinical tumor stage was the main source of heterogeneity. When these 11 studies were omitted, the heterogeneity was reduced, strongly establishing that patients with MBC should be analyzed separately to achieve additional optimal results5758.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of EMT-inducing Transcription Factors (EMT-TFs) in Metastatic Breast Cancer: A Systematic Review and Meta-analysis

Imani

Hosseinifard

Cheng

et al. 2016

Sci Rep

View full text Add to dashboard Cite

The epithelial-to-mesenchymal transition (EMT) is a vital control point in metastatic breast cancer (MBC). TWIST1, SNAIL1, SLUG, and ZEB1, as key EMT-inducing transcription factors (EMT-TFs), are involved in MBC through different signaling cascades. This updated meta-analysis was conducted to assess the correlation between the expression of EMT-TFs and prognostic value in MBC patients. A total of 3,218 MBC patients from fourteen eligible studies were evaluated. The pooled hazard ratios (HR) for EMT-TFs suggested that high EMT-TF expression was significantly associated with poor prognosis in MBC patients (HRs = 1.72; 95% confidence intervals (CIs) = 1.53–1.93; P = 0.001). In addition, the overexpression of SLUG was the most impactful on the risk of MBC compared with TWIST1 and SNAIL1, which sponsored fixed models. Strikingly, the increased risk of MBC was less associated with ZEB1 expression. However, the EMT-TF expression levels significantly increased the risk of MBC in the Asian population (HR = 2.11, 95% CI = 1.70–2.62) without any publication bias (t = 1.70, P = 0.11). These findings suggest that the overexpression of potentially TWIST1, SNAIL1 and especially SLUG play a key role in the aggregation of MBC treatment as well as in the improvement of follow-up plans in Asian MBC patients.

show abstract

“…Furthermore, a CTC count ≥ 5 indicated a worse treatment response in MBC patients [84]. The prognostic value of CTC enumeration has been demonstrated in abundant types of tumors, such as those in prostate cancer, lung cancer, pancreatic cancer and colorectal cancer, via large clinical trials and pooled analyses [85-89].…”

Section: Diagnosis and Prognosis Assessmentmentioning

confidence: 99%

Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?

Zhang¹,

Xia

et al. 2017

Cell Physiol Biochem

209

150

View full text Add to dashboard Cite

Precision medicine and personalized medicine are based on the development of biomarkers, and liquid biopsy has been reported to be able to detect biomarkers that carry information on tumor development and progression. Compared with traditional ‘solid biopsy’, which cannot always be performed to determine tumor dynamics, liquid biopsy has notable advantages in that it is a noninvasive modality that can provide diagnostic and prognostic information prior to treatment, during treatment and during progression. In this review, we describe the source, characteristics, technology for detection and current situation of circulating tumor cells, circulating free DNA and exosomes used for diagnosis, recurrence monitoring, prognosis assessment and medication planning.

show abstract

Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis

Cited by 62 publications

References 39 publications

Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

Prognostic Value of EMT-inducing Transcription Factors (EMT-TFs) in Metastatic Breast Cancer: A Systematic Review and Meta-analysis

Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?

Contact Info

Product

Resources

About